21 corporates have crossed the growth of IPM amongst the top 50
The Indian pharmaceutical market (IPM) clocked Rs 7375 crores in December 2014. It has grown at 13.6 per cent in the said month. Amongst the top 10, Ranbaxy grew by 28.7 per cent followed by Pfizer at 23.1 per cent and Sun Pharma at 21.5 per cent. 21 corporates have crossed the growth of IPM amongst the top 50.
Amongst the top 50 corporates, Akumentis has the highest growth of 69.4 per cent followed by Merck at 37.8 per cent and Albert David at 32 per cent. 30 corporates showed growths more than 10 per cent amongst the top 50. Amongst the 11-20 ranked corporates, Torrent has the highest growth of 31.1 per cent followed by Macleods at 30.1 per cent and USV at 24.9 per cent. Amongst the 51-60 ranked corporates, Panacea grows at 42 per cent followed by Pharmed at 17.7 per cent and Systopic at 17.2 per cent.
Amongst the 61-75 ranked corporates, Boehringer grew by 62.1 per cent followed by Tablets India at 23.3 per cent and Serdia at 18.8 per cent. Ranbaxy enters the Rs 3000-crore club, Panacea entered the Rs 300-crore club as on MAT December 2014.
Indian companies have grown at 12.1 per cent versus 17.5 per cent for MNCs in December 2014. Amongst the top 50 in MNCs, Merck grew by 37.8 per cent followed by Ranbaxy at 28.7 per cent, MSD at 26.1 per cent and Pfizer at 24.3 per cent.
With Bonus Units at Full Value | (Val in Crs) | |||||||
Val in Crs | Rank | MAT Dec -14 | Dec-14 | |||||
CORPORATE | MAT | MTH | Val (Cr) | MS% | GR% | Val (Cr) | MS% | GR% |
| IPM | 83009 | 100.00 | 10.2 | 7375 | 100.00 | 13.6 | ||
| Abbott + Abbott HC + Novo | 1 | 1 | 5136 | 6.19 | 6.9 | 484 | 6.56 | 17.7 |
| Sun Pharma | 2 | 2 | 4524 | 5.45 | 15.3 | 422 | 5.73 | 21.5 |
| Cipla | 3 | 3 | 4142 | 4.99 | 11.4 | 372 | 5.05 | 12.7 |
| Zydus + Biochem | 4 | 4 | 3604 | 4.34 | 8.7 | 315 | 4.27 | 12.6 |
| Ranbaxy | 5 | 5 | 3059 | 3.69 | 10.7 | 303 | 4.11 | 28.7 |
| Mankind | 6 | 6 | 2991 | 3.60 | 12.5 | 261 | 3.55 | 19.2 |
| Alkem + Cachet + Indchemie | 7 | 10 | 2912 | 3.51 | 11.1 | 236 | 3.20 | 3.6 |
| Glaxo | 8 | 9 | 2780 | 3.35 | -4.0 | 239 | 3.24 | 2.2 |
| Lupin | 9 | 8 | 2767 | 3.33 | 12.2 | 240 | 3.26 | 12.5 |
| Pfizer | 10 | 7 | 2472 | 2.98 | 12.7 | 241 | 3.26 | 24.3 |
| Macleods | 11 | 11 | 2406 | 2.90 | 26.6 | 215 | 2.91 | 30.1 |
| Emcure + Zuventus | 12 | 14 | 2218 | 2.67 | 7.4 | 189 | 2.57 | 2.0 |
| Intas | 13 | 13 | 2179 | 2.63 | 15.9 | 201 | 2.73 | 19.8 |
| Aristo | 14 | 17 | 2068 | 2.49 | 18.3 | 169 | 2.28 | 10.8 |
| Sanofi India | 15 | 12 | 2065 | 2.49 | 5.8 | 201 | 2.73 | 21.8 |
| Torrent | 16 | 16 | 1863 | 2.24 | 10.5 | 181 | 2.46 | 31.1 |
| Glenmark | 17 | 15 | 1820 | 2.19 | 15.2 | 182 | 2.46 | 21.2 |
| Dr. Reddys | 18 | 18 | 1755 | 2.11 | 9.0 | 161 | 2.19 | 12.8 |
| Micro + Bal | 19 | 20 | 1637 | 1.97 | 8.8 | 137 | 1.85 | 1.5 |
| USV | 20 | 19 | 1610 | 1.94 | 16.9 | 148 | 2.00 | 24.9 |
| Ipca | 21 | 21 | 1478 | 1.78 | 18.6 | 119 | 1.61 | 3.9 |
| Novartis | 22 | 22 | 1159 | 1.40 | 1.6 | 103 | 1.39 | 6.6 |
| Alembic | 23 | 23 | 1127 | 1.36 | 11.5 | 101 | 1.37 | 11.3 |
| Wockhardt | 24 | 24 | 983 | 1.18 | 1.7 | 85 | 1.16 | -3.4 |
| FDC | 25 | 27 | 839 | 1.01 | 5.2 | 62 | 0.85 | -3.1 |
Under the non-NLEM category Indian companies grew at 13.6 per cent whereas MNCs grew at 18 per cent. For the December quarter, the MNCs have shown a volume growth of 6.4 per cent versus one per cent for the Indian companies.
The DPCO containing molecules market grew at eight per cent whereas the non-DPCO market grew by 14.8 per cent resulting in an overall growth of 13.6 per cent for December 2014.
The NLEM and Non – NLEM category showed unit growth at 0.7 per cent and 3.2 per cent respectively. The DPCO 2013 portfolio for Pfizer grew at 13.9 per cent, GSK 1.7 per cent, Ranbaxy 41.9 per cent.
From therapy perspective four therapies have outgrown the IPM growth and 14 therapies have double digit growths. Respiratory market grew at 10 per cent, gastrointestinal market grew at 13.5 per cent, pain and analgesics market grew at 11.3 per cent whereas the anti-infectives grew at 5.2 per cent.
| Val in Crs | MAT Dec 14 | Month Dec-14 | ||
| Super Group | Val in Crs | GR% | Val in Crs | GR% |
| IPM | 83009 | 10.2 | 7375 | 13.6 |
| ANTI-INFECTIVES | 13272 | 6.0 | 1092 | 5.2 |
| CARDIAC | 10363 | 10.7 | 964 | 18.2 |
| GASTRO INTESTINAL | 9534 | 11.4 | 791 | 13.5 |
| VITAMINS / MINERALS / NUTRIENTS | 7537 | 11.1 | 643 | 12.6 |
| RESPIRATORY | 6481 | 10.4 | 656 | 10.0 |
| ANTI DIABETIC | 6278 | 21.3 | 615 | 33.1 |
| PAIN / ANALGESICS | 5912 | 9.3 | 506 | 11.3 |
| NEURO / CNS | 5064 | 8.2 | 460 | 15.4 |
| DERMA | 4772 | 16.1 | 450 | 19.6 |
| GYNAECOLOGICAL | 4209 | 5.1 | 352 | 8.1 |
| OPHTHAL / OTOLOGICALS | 1536 | 13.0 | 130 | 12.9 |
| HORMONES | 1402 | 4.8 | 123 | 6.2 |
| ANTI-NEOPLASTICS | 1355 | 25.5 | 119 | 12.7 |
| VACCINES | 1165 | – 8.0 | 103 | – 5.6 |
| BLOOD RELATED | 938 | 2.2 | 79 | 5.8 |
| OTHERS | 895 | 12.5 | 93 | 37.9 |
| UROLOGY | 877 | 21.5 | 80 | 29.7 |
| ANTI MALARIALS | 597 | 4.1 | 40 | – 4.2 |
| SEX STIMULANTS / REJUVENATORS | 461 | 4.1 | 47 | 18.8 |
| STOMATOLOGICALS | 362 | 12.1 | 31 | 13.2 |
The anti-diabetic market grows at 33.1 per cent and cardiac at 18.2 per cent in chronic business. The derma market grew by 19.6 per cent and urology market at 29.7 per cent.
From a regional perspective, 11 regions have outgrown the IPM growth. The Mumbai market grew the highest at 21.9 per cent followed by Gujarat market at 21.7 per cent and Kerala market at 20.7 per cent. No regions had negative growth in December 2014.
The Amoxycillin + Clavulanic Acid market grew at 8.2 per cent whereas Glimepiride + Metformin grows at 20 per cent at number two. The markets of paracetamol grew at 5.6 per cent, Atorvastatin 24 per cent, Probiotic Microbes at 26.9 per cent, Cefixime 1.1 per cent, Pantoprazole 15.3 per cent, Montelukast + Levocetrizine at 20.4 per cent, Glimepiride + Metformin + Pioglitazone at 28.1 per cent, Vitamin-D at 29.4 per cent, Hydroquinone + Mometasone + Tretinoin at 34.7 per cent, Voglibose + Metformin + Glimepiride at 57 per cent, Leveteracetam at 37.2 per cent, protein supplements at 24.1 per cent.
Mixtard continues to lead the pack with Rs 41.7 crores for December 2014 with a growth of 47.8 per cent. Mixtard grew at 47.8 per cent, Lantus grew at 36.7 per cent and Glycomet- GP grew at 36.3 per cent, Augmentin grows at 16.2 per cent, amongst the top 10 brands.
Amongst the brands who have gained ranks include Clexane (+64), Janumet (+54), Januvia (+43), Shelcal (+38), Panderm Plus (+31), Istamet (+29), Rosuvas & Jalra (+26), Novomix, Susten & Jalra-M (+17), Taxim, Pan & Levipil (+15), Zincovit (+13), Dexorange, Orofer-XT & Tonact (+9), Liv -52(+6), amongst Top 100 Brands over December 2013.
Total 361 SKUs and 185 brands launched in December 2014. Top new brands for December are Biovac V, Ryzodeg and Canmab. Two new subgroups got launched as Roflumilast and Cyclobenzaparine + Diclofenac.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -
Comments are closed.